Newswise — HUNTINGTON BEACH, Calif., Nov. 22, 2021 /PRNewswire/ — The Institute for Molecular Medicine (IMM), a non-profit research organization established in 1996 with the goal of understanding, preventing, and curing chronic diseases, including neurodegenerative disorders, today announced that it has been awarded an additional $3 million to the previously awarded $4.7 million grant from the National Institutes of Aging (NIA) of the NIH. The funding will support the manufacturing of a first-of-its-kind clinical cGMP grade dual vaccine, Duvax, that targets both pathological hallmarks of Alzheimer’s disease (AD), amyloid beta plaques (Aβ) and neurofibrillary tangles (tau).
First clinical trials of a dual vaccine for Alzheimer’s disease to begin in 2023
Current clinical data on AD biomarkers found in the brain and cerebrospinal fluid demonstrate that Aβ accumulation can precede…
